{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:28:08Z","timestamp":1790807288041,"version":"4.1.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"DOI":"10.1182\/bloodadvances.2024013474","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:21:38Z","timestamp":1736871698000},"page":"224-228","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912"],"prefix":"10.1182","volume":"9","author":[{"given":"Tait D.","family":"Shanafelt","sequence":"first","affiliation":[{"name":"1Department of Medicine, Stanford University, Stanford CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Victoria","family":"Wang","sequence":"additional","affiliation":[{"name":"2Dana Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Paietta","sequence":"additional","affiliation":[{"name":"4Department of Medicine (oncology), Montefiore Medical Center - Moses Campus, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of California Irvine Medical Center, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-5535","authenticated-orcid":false,"given":"Jacqueline","family":"Barrientos","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Northwell Health\/Center for Advanced Medicine, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Jelinek","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Mayo Clinic, Rochester, MN"},{"name":"7Department of Research, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-4830","authenticated-orcid":false,"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Mayo Clinic, Rochester, MN"},{"name":"7Department of Research, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Mayo Clinic, Rochester, MN"},{"name":"8Department of Medicine, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong Christine","family":"Zhang","sequence":"additional","affiliation":[{"name":"9Oncology, Kaiser Permanente National Community Oncology Research Program\/The Permanente Medical Group, Fresno, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Rochester University, Richester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Mato","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avina K.","family":"Singh","sequence":"additional","affiliation":[{"name":"13Medical Oncology and Hematology, Metro Minnesota Community Oncology Research Consortium, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Mullane","sequence":"additional","affiliation":[{"name":"14Hematology and Oncology, Aurora Cancer Care, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-1699","authenticated-orcid":false,"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[{"name":"15Cancer Treatment Evaluation Program, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-2189","authenticated-orcid":false,"given":"Harry","family":"Erba","sequence":"additional","affiliation":[{"name":"16Department of Medicine, The University of Alabama, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"17Medical Oncology\/Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[{"name":"18Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tallman","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[{"name":"18Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"5","key":"2025011416213340400_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025011416213340400_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2025011416213340400_bib3","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025011416213340400_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"23","key":"2025011416213340400_bib5","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025011416213340400_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10232","key":"2025011416213340400_bib7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without\u00a0obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"2025011416213340400_bib8","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and\u00a0supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"9747","key":"2025011416213340400_bib9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Clinical trial, phase III comparative study randomized controlled trial research support, non-U.S. gov't","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"2025011416213340400_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025011416213340400_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025011416213340400_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025011416213340400_bib13","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/224\/2350977\/blooda_adv-2024-013474-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/224\/2350977\/blooda_adv-2024-013474-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:21:44Z","timestamp":1736871704000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/224\/517473\/Tolerability-and-long-term-disease-control-by-IGHV"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013474","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}